Expression of a Splice Variant of CYP26B1 in Betel Quid-Related Oral Cancer

Expression of a Splice Variant of CYP26B1 in Betel Quid-Related Oral Cancer

Blog Article

Betel quid (BQ) is a psychostimulant, an addictive substance, and a group 1 carcinogen that exhibits the potential to induce adverse health effects.Approximately, 600 million users chew a variety of BQ.Areca nut (AN) is a necessary ingredient in BQ products.Arecoline is the primary alkaloid in the AN and can be metabolized through the cytochrome P450 (CYP) superfamily by inducing reactive oxygen species (ROS) production.Full-length read more CYP26B1 is related to the development of oral pharyngeal cancers.

We investigated whether a splice variant of CYP26B1 is associated with the occurrence of ROS related oral and pharyngeal cancer.Cytotoxicity assays were used to measure the effects of arecoline on cell viability in a dose-dependent manner.In vitro and in vivo studies were conducted to evaluate the expression of the CYP26B1 splice variant.The CYP26B1 splice variant exhibited lower expression than did full-length CYP26B1 in the human gingival fibroblast-1 dea eyewear and Ca9-22 cell models.Increased expression of the CYP26B1 splice variant was observed in human oral cancer tissue compared with adjacent normal tissue, and increased expression was observed in patients at a late tumor stage.

Our results suggested that the CYP26B1 splice variant is associated with the occurrence of BQ-related oral cancer.